Ultra-Sensitive Biosensor Can Detect the Diabetes Peptide Exendin-4 in Blood and Urine
A new nanoparticle-based biosensor detects exendin-4 at picomolar concentrations in blood and urine, potentially enabling point-of-care monitoring of peptide drug levels.
Quick Facts
What This Study Found
Researchers built a point-of-care electrochemical biosensor using cobalt nanoparticles embedded in nitrogen-doped hollow carbon nanostructures to detect exendin-4, a peptide drug used for type 2 diabetes. The best-performing sensor (Co3O4@HNCNs) detected exendin-4 at concentrations as low as 0.46 picomolar — an extremely sensitive threshold.
The sensor worked across a detection range of 1.0 to 90.0 pM with a sensitivity of 0.60 μA/pM. When tested on real human blood serum and urine samples, it achieved recovery rates of 96–104%, demonstrating practical accuracy for clinical use.
Key Numbers
LOD: 0.46 pM · detection range: 1.0–90.0 pM · sensitivity: 0.60 μA/pM · recovery in serum/urine: 96–104% · 3 cobalt nanostructure variants tested
How They Did This
Lab-based sensor development study. Three cobalt-based carbon nanostructure variants were synthesized and functionalized with anti-exendin-4 antibodies. Sensor performance was evaluated using chronoamperometry (measuring current changes over time). The best sensor was validated against spiked human blood serum and urine samples.
Why This Research Matters
Exendin-4 (the basis for the diabetes drug exenatide/Byetta) is part of the GLP-1 agonist family that has transformed diabetes and obesity treatment. Being able to detect tiny amounts of this peptide in blood or urine could help clinicians monitor drug levels, detect misuse in sports (it's banned by WADA), or verify medication adherence. A point-of-care sensor that works at picomolar sensitivity could bring peptide drug monitoring out of specialized labs and into clinics.
The Bigger Picture
As peptide drugs like GLP-1 agonists become some of the most prescribed medications globally, the need for simple, fast peptide detection tools is growing. This biosensor represents a broader trend toward point-of-care diagnostics for peptide therapeutics. If sensors like this reach clinical use, they could enable personalized dosing of peptide drugs, detect counterfeit medications, and support anti-doping testing for peptide hormones in sports.
What This Study Doesn't Tell Us
Tested only with spiked samples, not patient samples from people actually taking exendin-4. No head-to-head comparison with existing detection methods like ELISA or mass spectrometry. Long-term sensor stability, shelf life, and manufacturing scalability were not assessed. Real-world interference from other peptide drugs was not evaluated.
Questions This Raises
- ?Can this biosensor distinguish exendin-4 from structurally similar GLP-1 agonists like semaglutide or liraglutide?
- ?How does the sensor's performance compare to gold-standard methods like mass spectrometry for peptide detection?
- ?Could this platform be adapted to detect other therapeutic peptides beyond exendin-4?
Trust & Context
- Key Stat:
- 0.46 picomolar The sensor's detection limit — capable of finding exendin-4 at less than one trillionth of a mole per liter
- Evidence Grade:
- Preliminary evidence from lab-based sensor development and validation. The sensor shows impressive sensitivity and accuracy in controlled conditions, but has not been tested in real clinical scenarios with patient samples. Rated preliminary because translation to clinical use requires extensive further validation.
- Study Age:
- Published in 2025. This is very recent work reflecting the cutting edge of peptide biosensor technology. The platform is likely still in early development.
- Original Title:
- Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing.
- Published In:
- Biosensors & bioelectronics, 270, 116938 (2025)
- Authors:
- Zhang, Wei(11), Natarajan, Bharathi, Kannan, Palanisamy, Medlín, Rostislav, Nicolai, Laurent Christophe, Procházka, Michal, Minar, Jan, Subramanian, Palaniappan
- Database ID:
- RPEP-14536
Evidence Hierarchy
Frequently Asked Questions
What is exendin-4 and why would you need to detect it?
Exendin-4 is a peptide originally found in Gila monster venom that mimics the human hormone GLP-1. It's the basis for the diabetes drug exenatide (Byetta). Detecting it in blood or urine matters for monitoring drug levels in diabetes patients, testing for illegal use in sports (it's banned by WADA), and verifying medication quality.
How sensitive is 0.46 picomolar?
Extremely sensitive. A picomolar concentration is one trillionth of a mole per liter — roughly equivalent to detecting a single grain of sugar dissolved in an Olympic swimming pool. This level of sensitivity means the sensor can pick up very small amounts of the peptide that would be invisible to many standard lab tests.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14536APA
Zhang, Wei; Natarajan, Bharathi; Kannan, Palanisamy; Medlín, Rostislav; Nicolai, Laurent Christophe; Procházka, Michal; Minar, Jan; Subramanian, Palaniappan. (2025). Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing.. Biosensors & bioelectronics, 270, 116938. https://doi.org/10.1016/j.bios.2024.116938
MLA
Zhang, Wei, et al. "Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing.." Biosensors & bioelectronics, 2025. https://doi.org/10.1016/j.bios.2024.116938
RethinkPeptides
RethinkPeptides Research Database. "Rational construction of porous cobalt nanoparticle integrat..." RPEP-14536. Retrieved from https://rethinkpeptides.com/research/zhang-2025-rational-construction-of-porous
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.